Cue Biopharma, Inc. · NASDAQ:CUE
Cue Biopharma — Investor Presentation (May 2018)
21 slides from Cue Biopharma's investor presentation, May 17, 2018
Slide 1: Cue Biopharma Corporate Overview
Copyright © 2018. Cue Biopharma Corporate Overview Nasdaq: CUE May 17th, 2018 Exhibit 99
Slide 2: Forward Looking Statement
Forward Looking Statement This press presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by tho
Slide 3: Cue Biopharma Investment Highlights
Cue Biopharma Investment Highlights Scalable business for rapidly generating a pipeline of precision, injectable biologics for selectively modulating T cells Immuno-STAT™ (Selective Targeting and Alteration of T cells) Platform: A modular protein engineering solution to immunotherapy Planned IND sub
Slide 4: T Cells are Fundamental to a Healthy and Functional Immune System
T Cells are Fundamental to a Healthy and Functional Immune System T cells are key for providing protective immunity against pathogens and tumors (beneficial for the host) or for driving self-reactive responses in autoimmune diseases (detrimental to the host) Antigen-presenting cells (APCs) display p
Slide 5: Selectively Modulating Disease-Associated T Cells
Selectively Modulating Disease-Associated T Cells Immuno-STATs™ direct the potency of co-stimulatory ligands to antigen-specific T cell populations Fc Immuno-STAT™ Framework MHC - peptide (TCR Targeting) Co-stimulatory ligand(s) (Activating/Inhibitory Signal) IgG1 Fc Domain (Stability/Manufacturabil
Slide 6: T cell Modulation by Leveraging Specificity of T cell Receptors
T cell Modulation by Leveraging Specificity of T cell Receptors Immuno-STATs™ target TCRs on disease-associated T cells through their natural specific ligands: peptide-MHC (pMHC) Once the target TCR is bound, Immuno-STATs™ safely deliver potent immune activators to the T cell Activating signals stim
Slide 7: Targeted Delivery of IL-2 to Disease Associated T Cells
Targeted Delivery of IL-2 to Disease Associated T Cells Interleukin-2 (IL-2) is a highly-potent, well-validated T cell activator shown to synergize with anti-PD-1 IL-2 domain of CUE-100 has been modified to bias binding to the CD8+ T cells of interest Allowing the pMHC to guide binding: broad therap
Slide 8: CUE-101 is Exemplary Approach in Oncology
CUE-101 is Exemplary Approach in Oncology Rationale E7 protein is a tumor-specific driver of oncogenesis Highly immunogenic epitope HPV+ cancers affect ~25,000 Americans annually Extensive clinical characterization of IL-2 and Clinical data from ACT (Adoptive Cellular Therapy) targeting same T cell
Slide 9: Validating Immuno-STATs Through Human Ex Vivo Assays
Validating Immuno-STATs™ Through Human Ex Vivo Assays A highly-efficient translational approach to drug discovery + Extract Blood from Patients Isolate T cells Add IO-STAT™ to T cells Assay Selective Activation and Expansion Drug candidates are screened against human blood samples for selective acti
Slide 10: CUE-101 Expands Human HPV-Specific T Cells from Blood Samples
Expansion: CUE-101 Expands Human HPV-Specific T Cells from Blood Samples CUE-101 expands HPV reactive CD 8+ T cells from HPV+ donor Day 0 Day 17 Pre Stim CUE-101, 100nM 0.002% CD8+ T cells Antigen Specific T cells (HPV-E711-20 Tetramer) 0.086% Day 0 CUE-101 Stimulation Day 9 CUE-101 Re-stimulation D
Slide 11: Targeting IL-2 to Specific T cells Supports an Attractive Therapeutic Window
Engagement: Targeting IL-2 to Specific T cells Supports an Attractive Therapeutic Window Monitoring pSTAT5 on human PBMC supports >100 fold EC50 window HPV E711-20 CD8+ (EC50 = 2.8 nM) Bulk PBMC CUE-101 Off-target binding does not appear to emerge until very high doses: well beyond the dose range of
Slide 12: CUE-101 Activates Target T Cells into Cytotoxic Killer T Cells
CUE-101 Activates Target T Cells into Cytotoxic “Killer” T Cells CUE-101 treated HPV reactive human T cells show markers for cell killing ability CUE dose CUE-101 CUE-100 (CMV) 1.0 nM 3.2 nM 10.0 nM 31.7 nM 100 nM Media only PMA/iono 0.3 nM IFNg TNFa GrzB CUE-101 (HPV) (EC50 = 6.0 nM) CUE-100 (CMV)
Slide 13: Anti-tumor Efficacy in HPV-driven TC-1 Tumor Model with mCUE-101
Anti-tumor Efficacy in HPV-driven TC-1 Tumor Model with mCUE-101 Correlates with Increases in Target T cell Population Target T cell Population Vehicle mCUE-101 αPD-1 Combination 0/10 0/10 2/10 7/10
Slide 14: Previously Treated Mice Resist Tumor Re-challenge
Previously Treated Mice Resist Tumor Re-challenge: Demonstrates Immunological Memory Complete responders re-challenged after two months: no additional therapy given
Slide 15: Using Patient Samples to Select and Stratify Patients
Using Patient Samples to Select and Stratify Patients Potentially Provides a Translational Approach to Clinical Trials + Extract Blood from Patients Isolate T cells Add IO-STAT™ to T cells Assay Selective Activation and Expansion Patient samples may be tested prior to treatment to select and stratif
Slide 16: Ex Vivo Translational Studies Support Precision Medicine-Based Clinical Development
Ex Vivo Translational Studies Support Precision Medicine-Based Clinical Development CONFIDENTIAL & PROPRIETARY Leveraging Ex Vivo translational biology may lower clinical risk and increase speed to approval Phase I Phase II Phase III Phase I Phase II Ex Vivo Translational Dose Escalation Toxicity/Sa
Slide 17: Expanding the CUE-100 Series to New Indications
Expanding the CUE-100 Series to New Indications A simple peptide swap enables previously-validated framework to target new indications Different antigens on validated framework create new drugs Rapidly validates additional disease indications and pipeline Leveraging ex vivo assays to identify epitop
Slide 18: Immuno-STAT Platform for Targeting Autoimmune Diseases
Immuno-STAT™ Platform for Targeting Autoimmune Diseases Developing biologics to selectively ablate or inhibit disease-associated T cells Fc CUE MHC Class I Soluble pMHC I /II (CTL TCR Targeting) Co-Inhibitory/Regulatory CUE MHC Class II Directly depletes disease-associated cytolytic T cells (CTLs) r
Slide 19: Financial Summary and Capital Structure
Financial Summary and Capital Structure Initial Public Offering completed December 27, 2017 Issued 8,820,710 shares at a $7.50 Received approximately $62 million in net proceeds As of March 31, 2018: $280 million in market capitalization 20,130,766 common stock shares outstanding $53.1 million in ca
Slide 20: Potential Value Creating Activities for 2018-2019
Potential Value Creating Activities for 2018-2019 Planned submission of IND for CUE-101 in Q1 2019 Continue development of pipeline Nomination of new CUE-100 Series assets CUE-102/103 Ongoing data from human clinical samples in ex vivo assays Further development and refinement of ex vivo assay capab
Slide 21: Thank you
Thank you Copyright © 2018. Cue Biopharma